Literature DB >> 22711436

Erythropoietin protects against cisplatin-induced nephrotoxicity by attenuating endoplasmic reticulum stress-induced apoptosis.

Deyang Kong1, Li Zhuo, Changlu Gao, Suozhu Shi, Nan Wang, Zhiyong Huang, Wenge Li, Lirong Hao.   

Abstract

BACKGROUND: The anticancer drug cisplatin (CP)-induced nephrotoxicity associated with apoptosis plays crucial roles in tumor patients. Erythropoietin (EPO) has recently been shown to enhance recovery from CP-induced acute kidney injury (AKI) in rats by exerting anti-apoptotic effects. However, the molecular mechanisms of Erythropoietin protects against CP-induced AKI are not very clear. The present study investigated the protective effects of erythropoietin (EPO) against CP-induced nephrotoxicity and the possible mechanism in rats.
METHODS: Sprague-Dawley (SD) rats were randomly divided into four groups: (1) Control group (n=16): which received a single intraperitoneal injection of vehicle (0.9% saline; 5 mL/kg); (2) CP group (n=16): which received a single intraperitoneal injection of 10.0 mg/kg CP (previously dissolved at 2.0 mg/mL in 0.9% saline solution); (3) CP+rHuEPO group (n=16): which received rHuEPO (5000 U/kg) with co-injection of the LY294002 vehicle dimethyl sulfoxide (DMSO, 33.3 µL/kg; Sigma, St. Louis, MO, USA) by tail vein injection 2 days before CP administration, 15 min before CP administration, and 2 days after CP administration; (4) CP+rHuEPO+LY group (n=16): which received LY294002 (0.3 mg/kg) 10 min before rHuEPO administration by three injections into the tail vein at 2-day intervals beginning 2 days before CP administration. Apoptosis was assessed by the terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) method. The expressions of C/EBP-homologous protein (CHOP), glucose-regulated protein 78 (GRP78), caspase-12, the phosphorylation of Akt, cleaved-caspase-3 and EPO receptor (EPOR) were measured after CP-treated. In addition, light microscopy and immunohistochemistry examinations were performed.
RESULTS: The levels of serum urea and creatinine were increased at 96 h after CP-administered group. The eHuEPO-administered group had significantly lower serum creatinine levels. CP caused an increase in TUNEL-positive cells that was accompanied and apoptotic cell death induced by CP was significantly abrogated by rHuEPO at 96h by morphological evidence of apoptosis. The over-expression of CP-induced endoplasmic reticulum (ER) stress markers (CHOP and GRP78) and activation of caspase-12 were suppressed by rHuEPO, which also attenuated the CP-induced suppression of phosphatidylinositol-3kinase/Akt (PI3K/Akt) signaling in rat kidneys. In addition, LY294002 diminished the effect of rHuEPO on renal protection and antiapoptosis.
CONCLUSIONS: Injection of rHuEPO enhance recovery from CP-induced AKI in rats by ameliorating renal functional impairment and exerting important anti-apoptotic effects. However, rHuEPO inhibited CP-induced AKI by a possible mechanism involving PI3K/Akt activation and the inhibition of ER stress-mediated apoptosis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22711436     DOI: 10.5301/jn.5000177

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


  26 in total

Review 1.  Cellular and Molecular Mechanisms of AKI.

Authors:  Anupam Agarwal; Zheng Dong; Raymond Harris; Patrick Murray; Samir M Parikh; Mitchell H Rosner; John A Kellum; Claudio Ronco
Journal:  J Am Soc Nephrol       Date:  2016-02-09       Impact factor: 10.121

2.  Cisplatin nephrotoxicity in male beagle dogs: next-generation protein kidney safety biomarker tissue expression and related changes in urine.

Authors:  J E McDuffie; Y Chen; J Y Ma; S Lee; K M Lynch; D M Hamlin; L Nguyen; M Rizzolio; M Sonee; S Snook
Journal:  Toxicol Res (Camb)       Date:  2016-06-07       Impact factor: 3.524

Review 3.  Bridging translation for acute kidney injury with better preclinical modeling of human disease.

Authors:  Nataliya I Skrypnyk; Leah J Siskind; Sarah Faubel; Mark P de Caestecker
Journal:  Am J Physiol Renal Physiol       Date:  2016-03-09

4.  Epigallocatechin-3-gallate protects against cisplatin-induced nephrotoxicity by inhibiting endoplasmic reticulum stress-induced apoptosis.

Authors:  Binbin Chen; Guangyi Liu; Peimei Zou; Xing Li; Qiufa Hao; Bei Jiang; Xiangdong Yang; Zhao Hu
Journal:  Exp Biol Med (Maywood)       Date:  2015-02-25

Review 5.  Mechanisms of Cisplatin-Induced Acute Kidney Injury: Pathological Mechanisms, Pharmacological Interventions, and Genetic Mitigations.

Authors:  Kristen Renee McSweeney; Laura Kate Gadanec; Tawar Qaradakhi; Benazir Ashiana Ali; Anthony Zulli; Vasso Apostolopoulos
Journal:  Cancers (Basel)       Date:  2021-03-29       Impact factor: 6.639

Review 6.  Bridging Translation by Improving Preclinical Study Design in AKI.

Authors:  Mark de Caestecker; Ben D Humphreys; Kathleen D Liu; William H Fissell; Jorge Cerda; Thomas D Nolin; David Askenazi; Girish Mour; Frank E Harrell; Nick Pullen; Mark D Okusa; Sarah Faubel
Journal:  J Am Soc Nephrol       Date:  2015-11-04       Impact factor: 10.121

Review 7.  A new strategy of promoting cisplatin chemotherapeutic efficiency by targeting endoplasmic reticulum stress.

Authors:  Ye Xu; Chunyan Wang; Zhixin Li
Journal:  Mol Clin Oncol       Date:  2013-10-18

8.  Regulated cell death in cisplatin-induced AKI: relevance of myo-inositol metabolism.

Authors:  Fei Deng; Xiaoping Zheng; Isha Sharma; Yingbo Dai; Yinhuai Wang; Yashpal S Kanwar
Journal:  Am J Physiol Renal Physiol       Date:  2021-02-22

9.  ABCC1 is related to the protection of the distal nephron against hyperosmolality and high sodium environment: possible implications for cancer chemotherapy.

Authors:  Leonardo M Fonseca; Adriana B Alvarez; Rachel C Rodrigues; Diego H F Santos; Anibal G Lopes; Marcia A M Capella
Journal:  PLoS One       Date:  2013-06-28       Impact factor: 3.240

10.  Estrogen Abolishes Protective Effect of Erythropoietin against Cisplatin-Induced Nephrotoxicity in Ovariectomized Rats.

Authors:  Zahra Pezeshki; Mehdi Nematbakhsh; Safoora Mazaheri; Fatemeh Eshraghi-Jazi; Ardeshir Talebi; Hamid Nasri; Tahereh Safari; Azam Mansouri; Farzaneh Ashrafi
Journal:  ISRN Oncol       Date:  2012-11-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.